Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Searle CoKAR:SEARL +2.00%73 ROA % is 3.80% as of Mar. 2026, which is 63% below its 10-year median of 10.35. GuruFocus rates KAR:SEARL with a GF Score™ of 73/100 and a GF Value™ of ₨76.13 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 1,009 Drug Manufacturers companies, The Searle Co ranks worse than 51.64% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. The Searle Co's annualizedNet Income for the quarter that ended in Mar. 2026 was ₨1,966 Mil.
The Searle Co's average Total Assets over the quarter that ended in Mar. 2026 was ₨51,743 Mil. Therefore, The Searle Co's annualized ROA % for the quarter that ended in Mar. 2026 was 3.80%.
The historical rank and industry rank for The Searle Co's ROA % or its related term are showing as below:
KAR:SEARL'
s ROA % Range Over the Past 10 Years
Min: -3.77 Med: 10.35 Max: 20.45
Current: 2.41
During the past 13 years, The Searle Co's highest ROA % was 20.45%. The lowest was -3.77%. And the median was 10.35%.
KAR:SEARL's ROA % is ranked worse than 51.64% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 2.74
vs KAR:SEARL: 2.41
The Searle Co (KAR:SEARL) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
The Searle Co ROA % Related Terms
The Searle Co ROA % Historical Data
* Premium members only.
The historical data trend for The Searle Co's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, The Searle Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Searle Co ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The Searle Co's ROA % distribution charts can be found below:
* The bar in red indicates where The Searle Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
The Searle Co (KAR:SEARL) has a ROA % of 3.80% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on The Searle Co and its competitors. This is 63% below median its historical median of 10.35. According to the industry distribution chart, The Searle Co ranks #521 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 51.6%.
Is The Searle Co's ROA % too high?
The Searle Co's current ROA % of 3.80% is 63% below median its 10-year median of 10.35. The Drug Manufacturers industry median ROA % is 2.74. The Searle Co's value of 3.80% is 38.7% above this industry median. Based on the distribution chart, The Searle Co ranks #521 out of 1009 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, The Searle Co has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does The Searle Co's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, The Searle Co ranks #521 out of 1009 companies for ROA %. This places The Searle Co in the lower half of its industry. The industry median ROA % is 2.74. The Searle Co's value of 3.80% is 38.7% above this benchmark. While the company's 10-year median is 10.35 vs. the industry median of 2.74, The Searle Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.74, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Searle Co's current ROA % of 3.80% is 38.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on The Searle Co and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Searle Co's current ROA % is 3.80%, which is 63% below median its own 10-year median of 10.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Searle Co stock overvalued right now?
Based on GuruFocus' analysis, The Searle Co (KAR:SEARL) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨76.13, compared to a current price of ₨91.52 — trading 20.2% above its estimated fair value. The current ROA % is 3.80%, which is 63% below median its 10-year median of 10.35 and 38.7% above the Drug Manufacturers industry median of 2.74. The Searle Co's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For The Searle Co (KAR:SEARL), the current ROA % is 3.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Searle Co (KAR:SEARL) Overvalued in 2026?
Based on GuruFocus' analysis, The Searle Co stock appears to be overvalued.
The current stock price of ₨91.52 is trading 20.2% above its estimated GF Value™ of ₨76.13.
GuruFocus considers The Searle Co to be Modestly Overvalued.
Key valuation signals for KAR:SEARL:
ROA %: 3.80% (63% below median its 10-year median of 10.35)
GF Value™: ₨76.13 vs. price of ₨91.52 (20.2% above fair value)
Industry Position: 38.7% above the Drug Manufacturers median (#521 of 1009)
No single metric tells the full story. See the KAR:SEARL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Searle Co Ltd is principally engaged in the manufacturing and sale of pharmaceutical, consumer health, and nutritional products. It manufactures and sells products such as Semavi, Dalimab, Extor, Tramal, Rotec, Hylixi, Emsyn, and many more, focusing on various therapeutic areas like cardiovascular, antibiotics, nutrition, respiratory care, gastroenterology, oncology, hepatology, neurology and psychiatry, probiotics, antibiotics, and nutritional care. Additionally, the group offers medical devices and disposables, health supplements, and various nutritional consumable products. The majority of the group's revenue consists of pharmaceutical sales. Geographically, it generates maximum revenue from Pakistan, and rest from Sri Lanka, Cambodia, Myanmar, Oman, Vietnam, and other countries.
73GF Score
Get the complete analysis for KAR:SEARL
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:SEARL has been successfully added to your 
